ClinicalTrials.gg
CompletedNCT03979313MELODYUpdated Feb 28, 2024Results posted

A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY)

A Phase 3 interventional study of MEDI8897 and Placebo in Respiratory Syncytial Virus Infections, sponsored by AstraZeneca. Completed at 199 sites in 31 countries. Open to participants aged 0 Years to 1 Year, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-28.

Sponsored by AstraZeneca · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,012
Allocation
Randomized
Ages
0 Years to 1 Year
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies in Respiratory Syncytial Virus Infections by AstraZeneca — none open to participants now, none under way, none of them phase 3. Respiratory Syncytial Virus Infections · AstraZeneca.

Enrollment
2nd of 12
3,012 · median 239
Started
2019
with 1 other
Phase 3
3 of 14
none open now
Registered
12th of 14
by date

Among the 14 studies in Respiratory Syncytial Virus Infections by AstraZeneca, this one is the 2nd largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2019, is one of 3 in phase 3, and was the 12th registered.

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

None of the 14 studies in Respiratory Syncytial Virus Infections by AstraZeneca is open now. The open studies under Respiratory Syncytial Virus Infections, anywhere →

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: 0 Years to 1 Year · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies in Respiratory Syncytial Virus Infections by AstraZeneca as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and antidrug antibody (ADA) response for MEDI8897 in healthy late preterm and term infants who are 35 weeks or greater gestational age and entering their first RSV season.

Read the detailed description

This pivotal Phase 3 study will determine if MEDI8897 will prevent medically attended RSV-confirmed lower respiratory tract infections (LRTI) in healthy infants entering their first RSV season. The population to be enrolled is healthy late preterm and term infants born 35 weeks 0 days or greater gestational age (GA) who would not be eligible to receive RSV prophylaxis. A total of approximately 3,000 infants will be randomized 2:1 to receive either MEDI8897 or placebo. All subjects will be followed for approximately 510 days after dosing. Enrollment is planned at approximately 350 sites across the USA, Canada, Europe, Asia, and Southern Hemisphere.

03

Conditions studied

  • Respiratory Syncytial Virus Infections

Keywords

  • Respiratory Syncytial Virus
  • RSV
  • Late Preterm Infants
  • Healthy Infants
  • Lower Respiratory Tract Infection
04

Who can participate

Ages eligible
0 Years to 1 Year
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Healthy infants in their first year of life and born at or after 35 weeks 0 days GA
  • Infants who are entering their first RSV season at the time of screening

Key Exclusion Criteria:

  • Meets national or other local criteria to receive commercial palivizumab
  • Any fever (≥ 100.4°F [≥ 38.0°C], regardless of route) or acute illness within 7 days prior to randomization
  • Active RSV infection (a child with signs/symptoms of respiratory infection must have negative RSV testing) or known prior history of RSV infection
  • Receipt of palivizumab or other RSV monoclonal antibody or any RSV vaccine, including maternal RSV vaccination
05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
3,012 participants (actual)

Study arms

  • Experimental
    MEDI8897

    Anti-RSV monoclonal antibody with an extended half-life

    Drug: MEDI8897

  • Placebo comparator
    Placebo

    Commercially available 0.9% (w/v) saline

    Drug: Placebo

Interventions

  • Anti-RSV monoclonal antibody with an extended half-life

  • DrugPlacebo

    Commercially available 0.9% (w/v) saline

06

What researchers measure

Primary outcomes

  1. Number of Participants With MA RSV LRTI Through 150 Days Post Dose (Primary Cohort)

    Primary Endpoint Analysed on Primary Cohort Through 150 Days (N=1490 Participants)

    Time frame: Through 150 Days Post Dose

Secondary outcomes

  1. Number of Participants With MA RSV LRTI With Hospitalisation Through 150 Days Post Dose (Primary Cohort)

    Hospitalization Analysed on Primary Cohort Through 150 Days (N=1490 Participants)

    Time frame: Through 150 Days Post Dose

  2. Summary of Serum Concentrations (ug/mL) of MEDI8897 by Group

    Number of Subjects with at Least one Assessment

    Time frame: By visit until day 360 post dose

  3. Anti-drug Antibody Results by Visit (As Treated Population)

    Number of subjects with a positive result and a valid titer result at the specific visit

    Time frame: From baseline to 360 day post dose visit

Other outcomes

  1. Number of Participants With MA RSV LRTI Through 150 Days Post Dose (All Subjects)

    Primary Endpoint Analysed on All Subjects Through 150 Days (N=3012 participants)

    Time frame: Through 150 Days Post Dose

  2. Number of Participants With MA RSV LRTI With Hospitalisation Through 150 Days Post Dose (All Subjects)

    Hospitalization Analysed on All Subjects Through 150 Days (N=3012 participants)

    Time frame: Through 150 Days Post Dose

  3. Number of Participants With Disease From the 2nd RSV Season (All Subjects)

    Time frame: From Day 361 to Day 510 Post Dose

07

Results

Posted Feb 28, 2024

Participant flow

First Subject In: 23-07-2019. Last Subject Last Visit: 21-03-2023. The study was planned to analyze data on the full enrolment of approximately 3000 infants. The impact of the COVID-19 pandemic on RSV circulation led to the decision to analyze the primary endpoint based on the first 1500 subjects enrolled (Primary Cohort). After the COVID-19 pandemic the study restarted. So the study comprised 2 cohorts: a Primary and a Safety for a total of 3319 screened subjects.

Primary Cohort (Data Cut Off 11/3/2021)
Participant flow — Primary Cohort (Data Cut Off 11/3/2021)
MilestonePlaceboMedi8897
Started496994
Completed day 151 follow up488977
Completed day 361 follow up453914
Treated participants491994
Completed4389
Not completed453905
Withdrew: Lost to follow-up39
Withdrew: Any other reason34
Withdrew: Death04
Withdrew: Withdrawal by subject1420
Withdrew: Covid-19 pandemic13
Withdrew: Ongoing at the dco date432865
All Subjects
Participant flow — All Subjects
MilestonePlaceboMedi8897
Started10032009
Completed day 151 follow up9851977
Completed day 361 follow up9671944
Treated participants9971997
Completed9231873
Not completed80136
Withdrew: Any other reason1623
Withdrew: Covid-1913
Withdrew: Withdrawal by subject3544
Withdrew: Death05
Withdrew: Lost to follow-up2861

Outcome measures

SecondaryNumber of Participants With MA RSV LRTI With Hospitalisation Through 150 Days Post Dose (Primary Cohort)

Hospitalization Analysed on Primary Cohort Through 150 Days (N=1490 Participants)

Time frame:
Through 150 Days Post Dose
Reported as:
Count of participants · Participants
Number of Participants With MA RSV LRTI With Hospitalisation Through 150 Days Post Dose (Primary Cohort)
ParticipantsPlaceboMedi8897
Observed events through day 150 post dose86
Subjects requiring imputation (subjects without events and not followed through 150 days post dose)615
Subjects without event through day 150 post dose482973
Statistical analysis
  • Placebo vs Medi8897 · Poisson Model · p = 0.0708 · Relative risk reduction (rrr): 62.15 · 95% CI -8.57 to 86.80RRR of Medi8897 versus placebo; 95% CI and p-value estimated with Poisson regression with robust variance (including stratification factors \[age at randomisation\] as covariate) obtained after multiple imputation
PrimaryNumber of Participants With MA RSV LRTI Through 150 Days Post Dose (Primary Cohort)

Primary Endpoint Analysed on Primary Cohort Through 150 Days (N=1490 Participants)

Time frame:
Through 150 Days Post Dose
Reported as:
Count of participants · Participants
Number of Participants With MA RSV LRTI Through 150 Days Post Dose (Primary Cohort)
ParticipantsPlaceboMedi8897
Observed events through day 150 post dose2512
Subjects requiring imputation (Subjects without events and not followed through 150 days post dose)615
Subjects without event through day 150 post dose465967
Statistical analysis
  • Placebo vs Medi8897 · Poisson Model · p = <0.0001 · Relative risk reduction (rrr): 74.53 · 95% CI 49.63 to 87.12RRR of Medi8897 versus placebo; 95% CI and p-value estimated with Poisson regression with robust variance (including stratification factors \[age at randomisation\] as covariate) obtained after multiple imputation
Other pre-specifiedNumber of Participants With MA RSV LRTI Through 150 Days Post Dose (All Subjects)

Primary Endpoint Analysed on All Subjects Through 150 Days (N=3012 participants)

Time frame:
Through 150 Days Post Dose
Reported as:
Count of participants · Participants
Number of Participants With MA RSV LRTI Through 150 Days Post Dose (All Subjects)
ParticipantsPlaceboMedi8897
Observed events through day 150 post dose5424
Subjects requiring imputation (Subjects without events and not followed through 150 days post dose)1731
Subjects without event through day 150 post dose9321954
Statistical analysis
  • Placebo vs Medi8897 · Poisson Model · p = <0.0001 · Relative risk reduction (rrr): 76.36 · 95% CI 62.27 to 85.18RRR of Medi8897 versus placebo; 95% CI and p-value estimated with Poisson regression with robust variance (including stratification factors \[age at randomisation\] as covariate) obtained after multiple imputation
Other pre-specifiedNumber of Participants With MA RSV LRTI With Hospitalisation Through 150 Days Post Dose (All Subjects)

Hospitalization Analysed on All Subjects Through 150 Days (N=3012 participants)

Time frame:
Through 150 Days Post Dose
Reported as:
Count of participants · Participants
Number of Participants With MA RSV LRTI With Hospitalisation Through 150 Days Post Dose (All Subjects)
ParticipantsPlaceboMedi8897
Observed events through day 150 post dose209
Subjects requiring imputation (Subjects without events and not followed through 150 days post dose)1831
Subjects without event through day 150 post dose9651969
Statistical analysis
  • Placebo vs Medi8897 · Poisson Model · p = 0.0002 · Relative risk reduction (rrr): 76.84 · 95% CI 49.36 to 89.41RRR of Medi8897 versus placebo; 95% CI and p-value estimated with Poisson regression with robust variance (including stratification factors \[age at randomisation\] as covariate) obtained after multiple imputation
Other pre-specifiedNumber of Participants With Disease From the 2nd RSV Season (All Subjects)
Time frame:
From Day 361 to Day 510 Post Dose
Reported as:
Count of participants · Participants
Number of Participants With Disease From the 2nd RSV Season (All Subjects)
ParticipantsPlaceboMedi8897
MA RSV LRTI (protocol defined)1019
MA RSV LRTI hospitalisation (protocol defined)33
SecondarySummary of Serum Concentrations (ug/mL) of MEDI8897 by Group

Number of Subjects with at Least one Assessment

Time frame:
By visit until day 360 post dose
Reported as:
Geometric mean · ug/mL
Summary of Serum Concentrations (ug/mL) of MEDI8897 by Group
ug/mLMedi8897, 50 mgMedi8897, 100 mg
Day 7 Post Dose89.91 ± 39.3164.03 ± 15.8
Day 14 Post Dose74.09 ± 124.9105.05 ± 89.2
Day 30 Post Dose68.63 ± 58.6100.54 ± 90.1
Day 150 Post Dose18.32 ± 63.127.73 ± 62.9
Day 360 Post Dose1.75 ± 76.72.86 ± 85.7
SecondaryAnti-drug Antibody Results by Visit (As Treated Population)

Number of subjects with a positive result and a valid titer result at the specific visit

Time frame:
From baseline to 360 day post dose visit
Reported as:
Count of participants · Participants
Anti-drug Antibody Results by Visit (As Treated Population)
ParticipantsPlaceboMedi8897
Baseline44
Day 30 Post Dose214
Day 150 Post Dose121
Day 360 Post Dose1081

Adverse events

Collected over All-Cause Mortality monitored/assessed up to 510 days post dose . Adverse Events monitored/assessed up to day 360 post dose.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/997 (0%)83/997 (8.3%)836/997 (83.9%)
MEDI88975/1,997 (0.3%)149/1,997 (7.5%)1,717/1,997 (86%)
Most frequent serious events
Showing 10 of 109
Most frequent serious events
EventPlaceboMEDI8897
BronchiolitisInfections and infestations17/99727/1997
Respiratory syncytial virus bronchiolitisInfections and infestations10/9975/1997
GastroenteritisInfections and infestations5/99714/1997
PneumoniaInfections and infestations5/99713/1997
Urinary tract infectionInfections and infestations5/9977/1997
BronchitisInfections and infestations4/9973/1997
LaryngitisInfections and infestations3/9973/1997
PyrexiaGeneral disorders1/9976/1997
Lower respiratory tract infectionInfections and infestations0/9976/1997
Covid-19Infections and infestations2/9973/1997
Most frequent other events
Showing 10 of 565
Most frequent other events
EventPlaceboMEDI8897
Upper respiratory tract infectionInfections and infestations316/997639/1997
NasopharyngitisInfections and infestations237/997441/1997
PyrexiaGeneral disorders122/997290/1997
Dermatitis diaperSkin and subcutaneous tissue disorders103/997224/1997
RhinitisInfections and infestations102/997201/1997
GastroenteritisInfections and infestations100/997202/1997
DiarrhoeaGastrointestinal disorders89/997171/1997
Nasal congestionRespiratory, thoracic and mediastinal disorders86/997164/1997
Otitis mediaInfections and infestations76/997154/1997
RhinorrhoeaRespiratory, thoracic and mediastinal disorders65/997152/1997

Baseline characteristics

These are the Overall Number of All Subjects Population

Age, Continuous
Age, Continuous(Months)PlaceboMedi8897Total
Age (months) in Primary Cohort3.012 ± 2.25202.912 ± 2.20992.946 ± 2.2237
Age (months) in All Subjects2.918 ± 2.27402.905 ± 2.2202.909 ± 2.2376
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboMedi8897Total
Sex in Primary Cohort — Female257464721
Sex in Primary Cohort — Male239530769
Sex in All Subjects — Female5009381438
Sex in All Subjects — Male50310711574
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboMedi8897Total
Race in Primary Cohort — American Indian or Alaska Native265783
Race in Primary Cohort — Asian183654
Race in Primary Cohort — Black or African American136286422
Race in Primary Cohort — Native Hawaiian or other Pacific Islander5611
Race in Primary Cohort — White272524796
Race in Primary Cohort — Multiple categories checked11213
Race in Primary Cohort — Other3870108
Race in Primary Cohort — Missing033
Race in All Subjects — American Indian or Alaska Native5292144
Race in All Subjects — Asian50109159
Race in All Subjects — Black or African American138299437
Race in All Subjects — Native Hawaiian or other Pacific Islander81523
Race in All Subjects — White54110521593
Race in All Subjects — Multiple categories checked81927
Race in All Subjects — Other206420626
Race in All Subjects — Missing033
08

Study locations

199 sites
  • Research Site
    Birmingham, Alabama 35205, United States
  • Research Site
    Fort Defiance, Arizona 86504, United States
  • Research Site
    Fayetteville, Arkansas 72703, United States
  • Research Site
    Anaheim, California 92804, United States
  • Research Site
    Downey, California 90240, United States
  • Research Site
    National City, California 91950, United States
  • Research Site
    Paramount, California 90723, United States
  • Research Site
    West Covina, California 91790, United States
  • Research Site
    Aurora, Colorado 80015, United States
  • Research Site
    Colorado Springs, Colorado 80922, United States
  • Research Site
    Washington, District of Columbia 20016, United States
  • Research Site
    Gainesville, Florida 32653, United States
  • Research Site
    Hialeah, Florida 33012, United States
  • Research Site
    Miami, Florida 33142, United States
  • Research Site
    Atlanta, Georgia 30322, United States
  • Research Site
    Fort Gordon, Georgia 30905, United States
  • Research Site
    Chicago, Illinois 60611, United States
  • Research Site
    Oak Lawn, Illinois 60453, United States
  • Research Site
    Indianapolis, Indiana 46202, United States
  • Research Site
    West Des Moines, Iowa 50266, United States
  • Research Site
    Bardstown, Kentucky 40004, United States
  • Research Site
    Lexington, Kentucky 40517, United States
  • Research Site
    Shreveport, Louisiana 71105, United States
  • Research Site
    Jackson, Mississippi 39216, United States
  • Research Site
    Columbia, Missouri 65212, United States
  • Research Site
    Lincoln, Nebraska 68504, United States
  • Research Site
    Omaha, Nebraska 68114, United States
  • Research Site
    Gallup, New Mexico 87301, United States
  • Research Site
    Shiprock, New Mexico 87420, United States
  • Research Site
    Syracuse, New York 13210, United States
  • Research Site
    Boone, North Carolina 28607, United States
  • Research Site
    Cincinnati, Ohio 45229, United States
  • Research Site
    Cleveland, Ohio 44109, United States
  • Research Site
    Cleveland, Ohio 44121, United States
  • Research Site
    Columbus, Ohio 43205, United States
  • Research Site
    Dayton, Ohio 45406, United States
  • Research Site
    Dayton, Ohio 45414, United States
  • Research Site
    Oklahoma City, Oklahoma 73104, United States
  • Research Site
    Erie, Pennsylvania 16506, United States
  • Research Site
    Pittsburgh, Pennsylvania 15213, United States
  • Research Site
    Warwick, Rhode Island 02886, United States
  • Research Site
    North Charleston, South Carolina 29406, United States
  • Research Site
    Sioux Falls, South Dakota 57105, United States
  • Research Site
    Kingsport, Tennessee 37660, United States
  • Research Site
    Memphis, Tennessee 38103, United States
  • Research Site
    Tullahoma, Tennessee 37388, United States
  • Research Site
    Baytown, Texas 77521, United States
  • Research Site
    Dallas, Texas 75251, United States
  • Research Site
    Edinburg, Texas 78539, United States
  • Research Site
    League City, Texas 77573, United States
  • Research Site
    Longview, Texas 75605, United States
  • Research Site
    Pearland, Texas 77584, United States
  • Research Site
    San Antonio, Texas 78240, United States
  • Research Site
    San Antonio, Texas 78249, United States
  • Research Site
    Tomball, Texas 77375, United States
  • Research Site
    Layton, Utah 84041, United States
  • Research Site
    Roy, Utah 84067, United States
  • Research Site
    Saint George, Utah 84790, United States
  • Research Site
    Salt Lake City, Utah 84107, United States
  • Research Site
    Salt Lake City, Utah 84123, United States
  • Research Site
    South Jordan, Utah 84095, United States
  • Research Site
    Charlottesville, Virginia 22902, United States
  • Research Site
    Richmond, Virginia 23219, United States
  • Research Site
    Seattle, Washington 98105, United States
  • Research Site
    Morgantown, West Virginia 26506, United States
  • Research Site
    Marshfield, Wisconsin 54449, United States
  • Research Site
    San Miguel de Tucuman, 4000, Argentina
  • Research Site
    San Miguel de Tucuman, T4000NWB, Argentina
  • Research Site
    Clayton, 3168, Australia
  • Research Site
    Nedlands, 6009, Australia
  • Research Site
    Graz, 8036, Austria
  • Research Site
    Vienna, 1090, Austria
  • Research Site
    Brugge, 8000, Belgium
  • Research Site
    Brussels, 1070, Belgium
  • Research Site
    Brussels, 1090, Belgium
  • Research Site
    Bruxelles, 1000, Belgium
  • Research Site
    Gent, 9000, Belgium
  • Research Site
    Montana, 3400, Bulgaria
  • Research Site
    Pazardzhik, 4400, Bulgaria
  • Research Site
    Pleven, 5800, Bulgaria
  • Research Site
    Plovdiv, 4000, Bulgaria
  • Research Site
    Plovdiv, 4002, Bulgaria
  • Research Site
    Ruse, 7002, Bulgaria
  • Research Site
    Sofia, 1407, Bulgaria
  • Research Site
    Veliko Tarnovo, 5000, Bulgaria
  • Research Site
    Calgary, Alberta T3B 6A8, Canada
  • Research Site
    Vancouver, British Columbia V6H 3V4, Canada
  • Research Site
    Pierrefonds, Quebec H9H 4Y6, Canada
  • Research Site
    Santiago, 8880465, Chile
  • Research Site
    Cali, Colombia
  • Research Site
    Chia, 250002, Colombia
  • Research Site
    Medellin, 50036, Colombia
  • Research Site
    Medellin, 500515, Colombia
  • Research Site
    Monteria, 230002, Colombia
  • Research Site
    Soledad, 083001, Colombia
  • Research Site
    Havlickuv Brod, 580 22, Czechia
  • Research Site
    Paide, 72713, Estonia
  • Research Site
    Tallinn, 10117, Estonia
  • Research Site
    Tallinn, 10617, Estonia
  • Research Site
    Tallinn, 13419, Estonia

Showing the first 100 of 199 sites across 31 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, Muller WJ, Zar HJ, Brooks D, Grenham A, Wahlby Hamren U, Mankad VS, Ren P, Takas T, Abram ME, Leach A, Griffin MP, Villafana T; MELODY Study Group. Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants. N Engl J Med. 2022 Mar 3;386(9):837-846. doi: 10.1056/NEJMoa2110275. PubMed 35235726 ↗
  • Ginsburg AS, Srikantiah P. Respiratory syncytial virus: promising progress against a leading cause of pneumonia. Lancet Glob Health. 2021 Dec;9(12):e1644-e1645. doi: 10.1016/S2214-109X(21)00455-1. Epub 2021 Nov 11. No abstract available. PubMed 34774184 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2019 to primary completion in Mar 2021, 19 months.

Results were first posted in Feb 2024, 2 years 11 months after primary completion. A results delay was requested in Feb 2022.

Of 27 industry-sponsored phase 3 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 19. This study's 19 months is above that.

Counting every sponsor, half of 32 studies reached it within 8 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2019
First posted
Jun 7, 2019
StartActual
Jul 23, 2019
Primary completionActual
Mar 11, 2021
CompletionActual
Mar 21, 2023
Results delay requested
Feb 3, 2022
Results first posted
Feb 28, 2024
Last update
Feb 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03979313
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jun 7, 2019
Start date
Jul 23, 2019
Primary completion
Mar 11, 2021
Completion
Mar 21, 2023
Results posted
Feb 28, 2024
Last update
Feb 28, 2024

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nirsevimab

Start the discussion